The results revealed that NCTD component exhibits strong affinity for EZH2, as confirmed by molecular docking analysis (Figures 7A,B), suggesting that EZH2 may be a pivotal target of NCTD in the treatment of HCC. The gene discussed is EZH2; the disease is hepatocellular carcinoma.